Common adverse reactions The most common adverse reactions (≥20% of patients) listed in the prescribing information include:1 Headache Loss of appetite (pyrexia) Fall Abdominal pain Nasopharyngitis Cough Vomiting Nausea Serious adverse reactions The serious adverse reactions listed in the prescribing information include:1 Renal toxicity, including potentially fatal glomerulonephritis (kidney inflammation) Use in a specific population It is not yet known if Vyondys 53 (golodirsen) affects an unborn baby.1 For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.1 References 1. Full prescribing information [FDA]: Vyondys 53 (golodirsen) [PDF] Sarepta Therapeutics, Inc., Dec 2019 2. Duchenne muscular dystrophy: the basics Sarepta Therapeutics, last checked on Aug 27, 2020 3. Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment Nowak KJ, EMBO Rep. Sep 5, 2004 4. Sarepta Therapeutics Announces FDA Approval of VYONDYS 53 (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53 Sarepta Therapeutics press release, Dec 12, 2019